On the basis of two publications, which showed the effectiveness of Trk inhibitors in patients with different tumor entities including BC and NTRK fusions [307,308], Trk inhibitors for BC patients with NTRK fusions are recommended by the ESMO [256], the ASCO [271] and the AGO [148]. The gene discussed is NTRK1; the disease is neoplasm.